Meanwhile, HER3 upregulation frequently emerges as a resistance mechanism to MAPK/PI3K inhibitors, EGFR tyrosine kinase inhibitors ... is a G protein-coupled receptor (GPCR) that is overexpressed ...

RXFP1 is a G-protein-coupled receptor (GPCR) associated with various physiological functions ... Upon activation, RXFP1 influences signaling pathways such as phosphoinositide 3-kinase (PI3K)/Akt and ...

Additionally, ANO1 regulates multiple signaling pathways, including the epidermal growth factor receptor (EGFR) pathway, the mitogen-activated protein kinase (MAPK)/extracellular ... Additionally, ...

Dublin, May 06, 2025 (GLOBE NEWSWIRE) -- The "G-Protein Coupled Receptor (GPCR) Targeting: Technologies and Global Markets" report has been added to ResearchAndMarkets.com's offering. The global G ...

In this article, we are going to take a look at where Structure Therapeutics Inc. (NASDAQ:GPCR) stands against other promising small-cap stocks. Robert Teeter of Silvercrest Asset Management ...

The researchers analyzed chemokines and their associated G protein-coupled receptors (GPCRs), proteins that govern cell movement. They found that specific positions within structured and ...

Fintel reports that on May 2, 2025, Citigroup initiated coverage of Structure Therapeutics Inc. - Depositary Receipt () (NasdaqGM:GPCR) with a Buy recommendation. As of April 24, 2025, the average ...

The latest price target for Structure Therapeutics (NASDAQ:GPCR) was reported by HC Wainwright & Co. on May 12, 2025. The analyst firm set a price target for $75.00 expecting GPCR to rise to ...

This fundamental study explores a novel cellular mechanism underlying the degeneration of locus coeruleus neurons during chronic restraint stress. The evidence supporting the overexpression of LC ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...